These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 20920596

  • 21. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis.
    Marchesa P, Lashner BA, Lavery IC, Milsom J, Hull TL, Strong SA, Church JM, Navarro G, Fazio VW.
    Am J Gastroenterol; 1997 Aug; 92(8):1285-8. PubMed ID: 9260790
    [Abstract] [Full Text] [Related]

  • 22. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis.
    Saarinen S, Olerup O, Broomé U.
    Am J Gastroenterol; 2000 Nov; 95(11):3195-9. PubMed ID: 11095341
    [Abstract] [Full Text] [Related]

  • 23. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence.
    Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC.
    Am J Surg Pathol; 2007 Jun; 31(6):907-13. PubMed ID: 17527079
    [Abstract] [Full Text] [Related]

  • 24. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients.
    Jørgensen KK, Grzyb K, Lundin KE, Clausen OP, Aamodt G, Schrumpf E, Vatn MH, Boberg KM.
    Inflamm Bowel Dis; 2012 Mar; 18(3):536-45. PubMed ID: 21456044
    [Abstract] [Full Text] [Related]

  • 25. Hepatobiliary disease in inflammatory bowel disease.
    Balan V, LaRusso NF.
    Gastroenterol Clin North Am; 1995 Sep; 24(3):647-69. PubMed ID: 8809241
    [Abstract] [Full Text] [Related]

  • 26. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis.
    D'Haens GR, Lashner BA, Hanauer SB.
    Am J Gastroenterol; 1993 Aug; 88(8):1174-8. PubMed ID: 8338083
    [Abstract] [Full Text] [Related]

  • 27. Clinical differences between primary sclerosing cholangitis and sclerosing cholangitis with autoimmune pancreatitis.
    Nakazawa T, Ohara H, Sano H, Ando T, Aoki S, Kobayashi S, Okamoto T, Nomura T, Joh T, Itoh M.
    Pancreas; 2005 Jan; 30(1):20-5. PubMed ID: 15632695
    [Abstract] [Full Text] [Related]

  • 28. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis.
    Sano H, Nakazawa T, Ando T, Hayashi K, Naitoh I, Okumura F, Miyabe K, Yoshida M, Takahashi S, Ohara H, Joh T.
    J Hepatobiliary Pancreat Sci; 2011 Mar; 18(2):154-61. PubMed ID: 20740366
    [Abstract] [Full Text] [Related]

  • 29. The prevalence of inflammatory bowel disease in patients with primary sclerosing cholangitis.
    Osmanoğlu N, Tekin F, Ozütemiz O, Ersöz G, Tekeşin O.
    Turk J Gastroenterol; 2005 Dec; 16(4):240-1. PubMed ID: 16547857
    [No Abstract] [Full Text] [Related]

  • 30. Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis.
    Bergeron V, Vienne A, Sokol H, Seksik P, Nion-Larmurier I, Ruskone-Fourmestraux A, Svrcek M, Beaugerie L, Cosnes J.
    Am J Gastroenterol; 2010 Nov; 105(11):2405-11. PubMed ID: 20551939
    [Abstract] [Full Text] [Related]

  • 31. Chemoprevention and screening in primary sclerosing cholangitis.
    Kitiyakara T, Chapman RW.
    Postgrad Med J; 2008 May; 84(991):228-37. PubMed ID: 18508979
    [Abstract] [Full Text] [Related]

  • 32. [Primary sclerosing cholangitis and inflammatory bowel disease].
    Schrumpf E, Fausa O, Aadland E, Elgjo K, Kolmannskog F.
    Tidsskr Nor Laegeforen; 1990 Apr 10; 110(10):1212-6. PubMed ID: 1970674
    [Abstract] [Full Text] [Related]

  • 33. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
    Brackmann S, Andersen SN, Aamodt G, Langmark F, Clausen OP, Aadland E, Fausa O, Rydning A, Vatn MH.
    Scand J Gastroenterol; 2009 Apr 10; 44(1):46-55. PubMed ID: 18609187
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden.
    Bergquist A, Said K, Broomé U.
    Scand J Gastroenterol; 2007 Jan 10; 42(1):88-93. PubMed ID: 17190768
    [Abstract] [Full Text] [Related]

  • 36. Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis.
    Karlsen TH, Hampe J, Wiencke K, Schrumpf E, Thorsby E, Lie BA, Broomé U, Schreiber S, Boberg KM.
    Am J Gastroenterol; 2007 Jan 10; 102(1):115-21. PubMed ID: 17100974
    [Abstract] [Full Text] [Related]

  • 37. Fatigue in patients with primary sclerosing cholangitis.
    Björnsson E, Simren M, Olsson R, Chapman RW.
    Scand J Gastroenterol; 2004 Oct 10; 39(10):961-8. PubMed ID: 15513335
    [Abstract] [Full Text] [Related]

  • 38. Primary sclerosing cholangitis in Japanese patients: association with inflammatory bowel disease.
    Okada H, Mizuno M, Yamamoto K, Tsuji T.
    Acta Med Okayama; 1996 Oct 10; 50(5):227-35. PubMed ID: 8914675
    [Abstract] [Full Text] [Related]

  • 39. Primary sclerosing cholangitis in children: a histologic follow-up study.
    Batres LA, Russo P, Mathews M, Piccoli DA, Chuang E, Ruchelli E.
    Pediatr Dev Pathol; 2005 Oct 10; 8(5):568-76. PubMed ID: 16220233
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.